aTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University
August 10, 2021 08:00 ET
|
aTyr Pharma, Inc.
Collaboration led by Dr. Elliott Crouser to explore underlying cellular mechanisms of pulmonary sarcoidosis and identify potential sarcoidosis biomarkers. SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE)...
aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress
August 09, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
August 03, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung
July 29, 2021 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
July 08, 2021 08:00 ET
|
aTyr Pharma, Inc.
Results from proof-of-concept study are expected in September 2021. SAN DIEGO, July 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery...
aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis
June 23, 2021 08:00 ET
|
aTyr Pharma, Inc.
Event will feature Dr. Daniel Culver, Director of the Interstitial Lung Disease Program at the Cleveland Clinic. Conference call and webcast scheduled for Tuesday June 29th at 5:00pm ET/2:00pm PT. ...
aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody
June 10, 2021 16:30 ET
|
aTyr Pharma, Inc.
Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are...
aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen
May 25, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810
May 19, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update
May 13, 2021 16:05 ET
|
aTyr Pharma, Inc.
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter. Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and...